Ann Dermatol.  2019 Aug;31(4):479-482. 10.5021/ad.2019.31.4.479.

Effects of Eupatilin on Insulin-Like Growth Factor 1-Induced Lipogenesis and Inflammation of SZ95 Sebocytes

• Lee JH
• Lee YJ
• Song JY
• Kim YH
• Lee JY
• Zouboulis
• Park YM

• KMID: 2451494
• DOI: http://doi.org/10.5021/ad.2019.31.4.479

Abstract

No abstract available.

MeSH Terms

Inflammation*
Lipogenesis*

Figure

• 

  Fig. 1 Effects of eupatilin on the intracellular lipid synthesis of SZ95 sebocytes. With the exception of the control group, SZ95 sebocytes were pretreated with 50 ng/ml of insulin-like growth factor (IGF)-1 for 48 hours and then with 10 µg/ml or 100 µg/ml of eupatilin for 48 hours. (A) Intracellular lipid droplets of SZ95 sebocytes treated with eupatilin were detected by Oil Red O staining. Bars=20 µm. (B) Supernatant Oil Red O levels (%) were measured by their optical density at 500 nm. (C) Whole-cell lysates were prepared and analyzed by western blotting. Blots were incubated with antibodies specific for total and phosphorylated forms of Akt, peroxisome proliferator-activated receptor (PPAR)-γ, and mature sterol regulatory element-binding protein (SREBP)-1. (D) Quantitative reversetranscription polymerase chain reaction of PPARγ, SREBP-1a, and SREBP-1c for the evaluation of mRNA expression was performed. Data are presented as the mean±standard error of triplicate assay (n=5). Data were analyzed using the Student's t-test (*p<0.05, ***p<0.001). RFI: relative fold increase.

• 

  Fig. 2 Inhibition of insulin-like growth factor (IGF)-1-induced (pro)inflammatory cytokines of SZ95 sebocytes by eupatilin. With the exception of the control group, SZ95 sebocytes were treated with 50 ng/ml of IGF-1 for 48 hours and then with 10 µg/ml and 100 µg/ml of eupatilin for 48 hours. (A) Cells were incubated with primary antibody (nuclear factor kappa B [NF-κB] p65) and were finally visualized under a fluorescence microscope. (B) Quantitative Reverse-transcription polymerase chain reaction for the evaluation of mRNA expression of tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-8 was performed. Data are presented as the mean±standard error of triplicate assay (n=5). Data were analyzed using the Student's t-test (*p<0.05, **p<0.01, ***p<0.001). RFI: Relative fold increase.

Reference

1. Zouboulis CC. Acne and sebaceous gland function. Clin Dermatol. 2004; 22:360–366.

2. Melnik BC, Schmitz G. Role of insulin, insulin-like growth factor-1, hyperglycaemic food and milk consumption in the pathogenesis of acne vulgaris. Exp Dermatol. 2009; 18:833–841.

3. Lee JH, Lee YJ, Lee JY, Park YM. Topical application of Eupatilin ameliorates atopic dermatitis-like skin lesions in NC/Nga mice. Ann Dermatol. 2017; 29:61–68.

4. Choi EJ, Oh HM, Na BR, Ramesh TP, Lee HJ, Choi CS, et al. Eupatilin protects gastric epithelial cells from oxidative damage and down-regulates genes responsible for the cellular oxidative stress. Pharm Res. 2008; 25:1355–1364.

5. Lee SH, Bae EA, Park EK, Shin YW, Baek NI, Han EJ, et al. Inhibitory effect of Eupatilin and jaceosidin isolated from Artemisia princeps in IgE-induced hypersensitivity. Int Immunopharmacol. 2007; 7:1678–1684.

6. Engelking LJ, Kuriyama H, Hammer RE, Horton JD, Brown MS, Goldstein JL, et al. Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J Clin Invest. 2004; 113:1168–1175.

7. Smith TM, Gilliland K, Clawson GA, Thiboutot D. IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J Invest Dermatol. 2008; 128:1286–1293.

8. Trivedi NR, Cong Z, Nelson AM, Albert AJ, Rosamilia LL, Sivarajah S, et al. Peroxisome proliferator-activated receptors increase human sebum production. J Invest Dermatol. 2006; 126:2002–2009.

9. Ferré P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes. 2004; 53:Suppl 1. S43–S50.

10. Choi Y, Jung Y, Kim SN. Identification of Eupatilin from Artemisia argyi as a selective PPARα agonist using affinity selection ultrafiltration LC-MS. Molecules. 2015; 20:13753–13763.